Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Atogepant in Pediatric Episodic Migraine (Extension Study)
jRCT2051240027Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of atogepant in episodic migraine, sponsored by AbbVie Inc. Primary endpoints: Percentage of participants with adverse events, Percentage of participants with potentially clinically significant lab values and 6 more. Started May 2024; status: recruiting.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on jRCT2051240027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240027.